13MAY

Cytospire's £61m oncology Series A oversubscribed

3 min read

20:05UTC

Cytospire Therapeutics, a London biotech incorporated in February 2023, closed an oversubscribed £61m Series A on 5 May with the British Business Bank contributing £12m alongside international specialist funds.

← Back to State capital lands on UK tech in nine days Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Cytospire's oversubscribed £61m Series A at under three years old shows UK oncology attracts specialist international capital pre-clinical.

Cytospire Therapeutics, a London biotech incorporated in February 2023, closed an oversubscribed £61m Series A on 5 May 2026. 4BIO Capital led the round; Servier Ventures, Abingworth, LifeArc Ventures, Sound Bioventures, and Medical Incubator Japan participated. The British Business Bank (BBB) contributed £12m, drawing on the direct-investment mandate that activated in April 2026, the same instrument behind the £40m Quantum Motion cornerstone . ¹

Cytospire's lead programme, CYT X300, is a first-in-class pan-gamma delta T cell engager targeting EGFR (Epidermal Growth Factor Receptor)-positive solid tumours. Existing cancer immunotherapy approaches typically target specific gamma delta T cell subtypes; CYT X300 targets all subtypes simultaneously, which is the mechanism the company claims distinguishes it clinically. Funds from the Series A go toward IND-enabling (Investigational New Drug) studies and Good Manufacturing Practice (GMP) manufacturing ahead of a first-in-human trial.

CellCentric closed its Series D on the same day, drawing exclusively private institutional capital from US and European healthcare funds, plus Pfizer as a strategic participant; Cytospire drew the BBB as a public co-investor alongside international specialist biotech funds. Two UK oncology rounds, one calendar day, two entirely different capital structures. The DSIT Life Sciences Innovative Manufacturing Fund had already allocated over £80m to four regional manufacturing sites on 14 April , signalling that DSIT-adjacent capital is entering life sciences at multiple points along the development chain. The BBB's presence in a sub-£100m Series A where private capital was already oversubscribing raises the additionality question the mandate was supposed to address: the fund is entering rounds where demand already exceeds supply, not rounds where private capital has declined to participate.

For UK oncology founders, the data point is the oversubscription at less than three years from incorporation: a first-in-class mechanism, no clinical data yet, and specialist international co-investors willing to lead. The BBB's £12m did not anchor the round; 4BIO Capital led it.

Deep Analysis

In plain English

Cytospire has developed a cancer treatment that works by recruiting a type of immune cell called gamma delta T cells to attack tumours. Existing cancer immunotherapies target specific subtypes of these cells; Cytospire's drug, CYT X300, is designed to engage all of them at once, potentially treating a wider range of patients with EGFR-positive solid tumours, a category that includes some lung, colorectal, and head and neck cancers. The company raised £61m in May 2026, just over three years after it was founded in London. The British Business Bank put in £12m alongside specialist cancer investment funds from the UK, France, Japan, and the US. The money funds safety testing studies and manufacturing preparation before the first clinical trial in humans.

Deep Analysis

Root Causes

The BBB's £12m contribution to an oversubscribed Series A illustrates the additionality question embedded in the new mandate.

Private capital led by 4BIO Capital and backed by Servier Ventures, Abingworth, and LifeArc Ventures had already pushed the round past its target. The BBB entered a round where private institutional appetite exceeded supply, which is the opposite of the seed-gap market failure the mandate was designed to address.

What could happen next?

Opportunity
Cytospire's international syndicate including Medical Incubator Japan positions the company for early Asian licensing discussions, a capital-efficient route to funding Phase 1 without requiring a US listing.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: The 2016 to 2019 wave of UK CAR-T (chimeric antigen receptor T cell) companies, including Autolus Therapeutics (UCL spinout, listed on Nasdaq 2018), showed that British academic immunotherapy programmes can attract international Series A capital before clinical proof of concept when the mechanism is genuinely first-in-class.

Autolus raised £120m in its 2018 IPO on the strength of preclinical and Phase 1 data. Cytospire is following the same pattern at the same stage with a different T cell modality.

Counter-parallel: Kymera Therapeutics, a Boston immunotherapy company, raised $102m in a 2021 Series C on targeted protein degradation; its lead programme entered Phase 2 in 2023 but produced a clinical hold in 2024. First-in-class mechanism does not guarantee clinical success, and Cytospire's IND-enabling stage means investors are pricing in a multi-year clinical risk period with no human safety data yet.

At £61m Series A for a company incorporated in February 2023, Cytospire's implied post-money valuation positions it at the upper end of preclinical UK biotech, consistent with first-in-class mechanism pricing by specialist institutional funds.

The Japanese co-investor Medical Incubator Japan signals that Asian pharma groups are monitoring UK oncology immunotherapy for licensing optionality, which compresses the timeline to a potential non-dilutive licensing deal alongside the clinical programme.

Consensus view: 4BIO Capital's managing partners assess pan-gamma delta T cell engagers as a clinically distinct approach to solid tumour immunotherapy: unlike checkpoint inhibitors (pembrolizumab, nivolumab) which release existing T cell activity, CYT X300 recruits gamma delta T cells as effectors across the full heterogeneous population of EGFR-positive tumour subtypes.

The oversubscription at less than three years from incorporation reflects specialist investors pricing clinical optionality before Phase 1 data.

Counter-view: The Francis Crick Institute's immunology group notes that pan-gamma delta engagement has produced cytokine release syndrome in preclinical models. First-in-human trial design will require careful dose-escalation protocols, and the IND-enabling stage that Cytospire is funding carries significant safety risk before efficacy data exist.

Key tension: Whether pan-gamma delta T cell engagement can maintain tumour selectivity across heterogeneous patient populations without triggering systemic immune responses that limit the therapeutic window.

First Reported In

Update #4 · State capital lands on UK tech in nine days

BioSpace (via GlobeNewswire)· 13 May 2026

Read original →

Causes and effects

Caused by

Business Bank begins direct startup investment

The BBB's £12m Cytospire co-investment is direct-mandate capital under the £6.6bn expansion activated in April 2026 (ID:2343).

Occurred 6 Apr 2026

Read story →

This Event

Cytospire's £61m oncology Series A oversubscribed

Cytospire's oversubscribed round at less than three years old shows that UK oncology immunotherapy companies with first-in-class mechanisms can attract large Series A rounds from international specialist capital, with public co-investment from the BBB entering rounds where private institutional appetite is already present.

Different Perspectives

Australian Department of Defence (AUKUS AI for Acoustics partner)

Rowden Technologies holds active AUKUS AI for Acoustics contracts with the UK, US, and Australian defence establishments. The NWF's £25m investment in Rowden on 13 May brings UK sovereign capital directly into a trilateral programme, which from Canberra's perspective places additional UK government skin-in-the-game on a programme Australia co-funds and co-develops.

Sofinnova Partners (European VC co-investor in Cytospire Series A)

Sofinnova participated alongside the BBB in Cytospire's oversubscribed £61m Series A on 5 May, demonstrating that the BBB's expanded direct mandate is attracting established European specialist biotech funds rather than replacing them. European VCs see the BBB's cornerstone position as a signal reducing UK biotech execution risk rather than crowding out private capital.

Temasek (Singapore sovereign co-investor in Isomorphic Series B)

Singapore's Temasek co-invested alongside the UK's SAIU in Isomorphic's $2.1bn round, treating the same Alphabet-majority company as an acceptable sovereign co-investment target. Temasek's participation normalises the structure: multiple sovereign wealth funds backed the same round, strengthening the precedent that UK-headquartered Alphabet subsidiaries qualify for state investment.

Alphabet / Google (majority Isomorphic shareholder, Mountain View)

Alphabet co-invested via GV and CapitalG in the same Isomorphic Series B round that received UK sovereign backing, placing US corporate capital and UK public capital in the same syndicate without any governance asymmetry. SAIU's minority stake validates Isomorphic's strategic value without constraining Alphabet's control over IP, geography, or exit decisions.

DSIT / Liz Kendall, Secretary of State for Science

DSIT framed the Isomorphic investment as backing a British-founded and headquartered company advancing UK AI capability, and described the nine-day sovereign deployment sprint as evidence the government's industrial strategy is operational. The department has not addressed the ownership question, the absence of eligibility criteria, or the pace-versus-doctrine tension in the BBB mandate.

Beauhurst / UK startup data analysts

Five sub-£50m rounds closed in nine days with zero VCT-backed angel networks on any cap table, confirming the post-cut investor map is forming fast in the £4m–£40m band. The gap is structural: 36.7% of university spinouts raised below £500,000 in 2025, a tier neither the SAIU nor the BBB direct mandate touches.